Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BETA INNOV operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This 1 pending office action represents the current focus of the company's patent prosecution efforts. A portfolio with this level of activity often indicates a specific stage of intellectual property development in the biotech sector.
The portfolio's examination is concentrated, involving 1 distinct examiner and 1 distinct art unit. By being limited to 1 distinct art unit, the company's current filings are subject to the specific examination standards of a single technical group. This centralization can lead to a more predictable prosecution experience as the applicant deals with the 1 distinct art unit and its associated examiner.
KUCHARCZK, JED A is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. As there is 1 pending office action in total, this examiner manages the company's active patent review. The 1 busiest examiner pending office action highlights a prosecution strategy that is currently focused on a single point of contact at the patent office, specifically the 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.4% | +16.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258112 | COMPOSITION CONTAINING A 7BETA-HYDROXYCHOLESTEROL AND A LIPID VEHICLE, AND ITS USE IN THE TREATMENT OF NEOPLASTIC PATHOLOGIES | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17258112 | COMPOSITION CONTAINING A 7BETA-HYDROXYCHOLESTEROL AND A LIPID VEHICLE, AND ITS USE IN THE TREATMENT OF NEOPLASTIC PATHOLOGIES | KUCHARCZK, JED A | 1623 | — | Non-Final OA | — | Pending | Jan 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBETA INNOV has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jed A Kucharczk has the most, with 1 of BETA INNOV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
